Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV001010532 | SCV001170748 | uncertain significance | Hereditary cancer-predisposing syndrome | 2019-08-27 | criteria provided, single submitter | clinical testing | The c.1246-2A>G intronic variant results from an A to G substitution two nucleotides upstream from coding exon 9 in the RAD50 gene. This nucleotide position is highly conserved in available vertebrate species. Using the Human Splicing Finder (HSF) splice site prediction tool, this alteration is predicted to abolish the weakly predicted native splice acceptor; however, direct evidence is unavailable (Desmet FO et al. Nucleic Acids Res. 2009 May;37:e67). In addition, the BDGP and ESEfinder in silico splicing models do not produce a reliable prediction for this splice acceptor site, therefore the predicted impact of this alteration on splicing cannot be determined at this time. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |